Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2026

Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview

• The Rituxan Hycela, Rituxan Mabthera (Rituximab) market growth in the historic period has been driven by increasing prevalence of non-hodgkin lymphoma, rising incidence of autoimmune diseases • Market expansion is supported by increasing penetration of biosimilar rituximab products, rising demand for outpatient oncology treatments • Growth Driver: Rising Prevalence Of Autoimmune Diseases Driving Growth Of The Market • Market Trend: Adoption Of Rituximab Biosimilars To Improve Patient Access And Reduce Treatment Costs • North America was the largest region in 2025.

What Is Covered Under Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

Rituxan hycela and rituxan mabthera (rituximab) are monoclonal antibody therapies targeting CD20-positive B-cells. They are used to treat conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases such as rheumatoid arthritis. Rituxan hycela is a subcutaneous formulation, while rituxan mabthera is administered intravenously. The main types of rituxan hycela, rituxan mabthera (rituximab) are 10 ml and 50 ml. The 10ml vial of rituxan hycela is designed for patients who need a smaller dose of the medication. This size is often suitable for those starting treatment or requiring lower dosages, ensuring individualized care. It is administrated through the route of subcutaneous, intravenous, and parenteral and is distributed through hospital pharmacies, online pharmacies, and others. It has applications in non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others.

What Is The Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Growth Forecast?

The rituxan hycela, rituxan mabthera (rituximab) market size is expected to see rapid growth in the next few years. It will grow to $7285.24 million in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to increasing penetration of biosimilar rituximab products, rising demand for outpatient oncology treatments, expansion of subcutaneous biologics, growing focus on cost-effective biologic therapies, increasing approvals in emerging markets. Major trends in the forecast period include increasing adoption of subcutaneous rituximab formulations, rising use of monoclonal antibody therapies, expansion of indications across oncology and autoimmune disorders, growing preference for shorter administration times, enhanced focus on biosimilar competition.

Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Segmentation

1) By Type: 10ml, 50ml 2) By Route Of Administration: Subcutaneous, Intravenous, Parenteral 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels 4) By Application: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications

What Are The Drivers Of The Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of the rituxan hycela, rituxan mabthera (rituximab) market going forward. Autoimmune diseases refer to conditions in which the immune system mistakenly attacks healthy tissues, leading to chronic inflammation and organ damage. The prevalence of autoimmune diseases is increasing as more healthcare providers and patients recognize the importance of early diagnosis, effective management, and access to targeted therapies to control disease progression and improve quality of life. Rituxan Hycela and rituxan mabthera (rituximab) play a crucial role in the rising prevalence of autoimmune diseases by controlling disease progression and improving patient outcomes through targeted B cell depletion. For instance, in March 2023, according to the Society for Women’s Health Research, a US-based non-profit organization, the autoimmune diseases are estimated to affect 23.5 million to 50 million. Globally, the rates of autoimmune diseases are rising by between 3 and 9 percent each year. Therefore, the rising prevalence of autoimmune diseases is driving growth of the rituxan hycela, rituxan mabthera (rituximab) industry. Rising healthcare expenditure is expected to propel the growth of the rituxan hycela and rituxan mabthera (rituximab) market going forward. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. Healthcare expenditure is rising due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure enhances access to advanced treatments such as rituxan hycela and rituxan or mabthera (rituximab), driving demand for effective therapies in oncology and autoimmune diseases. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Therefore, the rising healthcare expenditure is driving the rituxan hycela and rituxan mabthera (rituximab) market.

Key Players In The Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

Major companies operating in the rituxan hycela, rituxan mabthera (rituximab) market are F. Hoffmann-La Roche AG (Genentech Inc.)

Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Trends and Insights

Major companies are operating the rituxan hycela and rituxan mabthera (rituximab) market, focusing on developing technological advancements such as biosimilar anti-CD20 monoclonal antibodies to enhance patient access, reduce treatment costs, and maintain clinical efficacy comparable to originator rituximab. A biosimilar monoclonal antibody is a biologic drug engineered to closely mimic the reference rituximab (Rituxan/MabThera) in structure and function binding to the CD20 antigen on B cells to achieve the same therapeutic effect while offering improved affordability and accessibility. For instance, in July 2023, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, announced that its rituximab biosimilar DRL_RI (proposed brand name ITUXREDI) was accepted by the U.S. FDA for review. The product demonstrates the same amino acid sequence, mechanism of action, and clinical outcomes as the reference rituximab, and is indicated for multiple conditions, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and vasculitis, thereby expanding patient access to critical therapies.

Regional Insights

North America was the largest region in the rituxan hycela, rituxan mabthera (rituximab) market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

The rituxan hycela and rituxan mabthera (rituximab) market consists of sales of MabThera 1600 mg and ritunxan hycela (rituximab and hyaluronidase human injection). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2026?

The rituxan hycela, rituxan mabthera (rituximab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rituxan hycela, rituxan mabthera (rituximab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.